CN114425024A - 含有氢醌或其衍生物的稳定化组合物 - Google Patents
含有氢醌或其衍生物的稳定化组合物 Download PDFInfo
- Publication number
- CN114425024A CN114425024A CN202111197165.9A CN202111197165A CN114425024A CN 114425024 A CN114425024 A CN 114425024A CN 202111197165 A CN202111197165 A CN 202111197165A CN 114425024 A CN114425024 A CN 114425024A
- Authority
- CN
- China
- Prior art keywords
- acid
- hydroquinone
- composition
- sodium
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 title claims abstract description 262
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 239000011787 zinc oxide Substances 0.000 claims abstract description 32
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 32
- 229940105847 calamine Drugs 0.000 claims abstract description 25
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 25
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 25
- 150000004706 metal oxides Chemical class 0.000 claims abstract description 25
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 25
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 22
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 18
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract description 18
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 18
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 10
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims abstract description 7
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 12
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229960000271 arbutin Drugs 0.000 claims description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- -1 hydroquinone glucoside Chemical class 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 claims description 3
- LKVFCSWBKOVHAH-UHFFFAOYSA-N 4-Ethoxyphenol Chemical compound CCOC1=CC=C(O)C=C1 LKVFCSWBKOVHAH-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000001361 adipic acid Substances 0.000 claims description 3
- 235000011037 adipic acid Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 229960000990 monobenzone Drugs 0.000 claims description 3
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 claims description 2
- STGNLGBPLOVYMA-TZKOHIRVSA-N (z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O STGNLGBPLOVYMA-TZKOHIRVSA-N 0.000 claims description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 claims description 2
- TWHCNIAWRGZIFI-UHFFFAOYSA-N 1-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O.OC(=O)C(O)C(C(O)=O)CC(O)=O TWHCNIAWRGZIFI-UHFFFAOYSA-N 0.000 claims description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 claims description 2
- GFBCWCDNXDKFRH-UHFFFAOYSA-N 4-(oxan-2-yloxy)phenol Chemical class C1=CC(O)=CC=C1OC1OCCCC1 GFBCWCDNXDKFRH-UHFFFAOYSA-N 0.000 claims description 2
- HJRGXHLPICBGPA-UHFFFAOYSA-N 4-(thian-2-yloxy)phenol Chemical class C1=CC(O)=CC=C1OC1SCCCC1 HJRGXHLPICBGPA-UHFFFAOYSA-N 0.000 claims description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical class CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 2
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- XEUHNWODXVYLFD-UHFFFAOYSA-N heptanedioic acid Chemical compound OC(=O)CCCCCC(O)=O.OC(=O)CCCCCC(O)=O XEUHNWODXVYLFD-UHFFFAOYSA-N 0.000 claims description 2
- YVSCCMNRWFOKDU-UHFFFAOYSA-N hexanedioic acid Chemical compound OC(=O)CCCCC(O)=O.OC(=O)CCCCC(O)=O YVSCCMNRWFOKDU-UHFFFAOYSA-N 0.000 claims description 2
- WPBWJEYRHXACLR-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O.OC(=O)CCCCCCCC(O)=O WPBWJEYRHXACLR-UHFFFAOYSA-N 0.000 claims description 2
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 claims description 2
- PFGGBVOALJVMTI-UHFFFAOYSA-N prop-1-ene-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O.OC(=O)CC(C(O)=O)=CC(O)=O PFGGBVOALJVMTI-UHFFFAOYSA-N 0.000 claims description 2
- HJSRRUNWOFLQRG-UHFFFAOYSA-N propanedioic acid Chemical compound OC(=O)CC(O)=O.OC(=O)CC(O)=O HJSRRUNWOFLQRG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 2
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 claims 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract description 16
- 230000002087 whitening effect Effects 0.000 abstract description 12
- 206010040880 Skin irritation Diseases 0.000 abstract description 10
- 230000036556 skin irritation Effects 0.000 abstract description 10
- 231100000475 skin irritation Toxicity 0.000 abstract description 10
- 239000004615 ingredient Substances 0.000 abstract description 9
- 239000004408 titanium dioxide Substances 0.000 abstract description 8
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 description 21
- 235000006708 antioxidants Nutrition 0.000 description 21
- 238000002845 discoloration Methods 0.000 description 20
- 239000002537 cosmetic Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-SQOUGZDYSA-N beta-D-arabinopyranose Chemical compound O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-KLVWXMOXSA-N beta-L-arabinopyranose Chemical compound O[C@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KLVWXMOXSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-GKFJPSPNSA-N (2r,3s,4s,5r,6s)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound N[C@@H]1[C@H](O)O[C@@H](CO)[C@H](O)[C@H]1O MSWZFWKMSRAUBD-GKFJPSPNSA-N 0.000 description 2
- MSWZFWKMSRAUBD-VFUOTHLCSA-N 2-amino-2-deoxy-beta-D-galactopyranose Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-VFUOTHLCSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- SRBFZHDQGSBBOR-MBMOQRBOSA-N alpha-D-arabinopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-MBMOQRBOSA-N 0.000 description 2
- MSWZFWKMSRAUBD-DVKNGEFBSA-N alpha-D-galactosamine Chemical compound N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-DVKNGEFBSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- MSWZFWKMSRAUBD-UKFBFLRUSA-N alpha-D-glucosamine Chemical compound N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-UKFBFLRUSA-N 0.000 description 2
- HMFHBZSHGGEWLO-AIHAYLRMSA-N alpha-D-ribose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-AIHAYLRMSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SXUWKVJYSA-N alpha-L-galactose Chemical compound OC[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-SXUWKVJYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-ORELYVPDSA-N alpha-L-glucopyranuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-ORELYVPDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-MDMQIMBFSA-N alpha-L-glucose Chemical compound OC[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-MDMQIMBFSA-N 0.000 description 2
- HMFHBZSHGGEWLO-NEEWWZBLSA-N alpha-L-ribose Chemical compound OC[C@@H]1O[C@@H](O)[C@@H](O)[C@H]1O HMFHBZSHGGEWLO-NEEWWZBLSA-N 0.000 description 2
- MSWZFWKMSRAUBD-YDMGZANHSA-N beta-D-Glucosamine Natural products N[C@H]1[C@H](O)O[C@@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-YDMGZANHSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N beta-D-galacturonic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 2
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-KGJVWPDLSA-N beta-L-galactose Chemical compound OC[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-KGJVWPDLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QYESYBIKSA-N beta-L-glucose Chemical compound OC[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-QYESYBIKSA-N 0.000 description 2
- HMFHBZSHGGEWLO-FCAWWPLPSA-N beta-L-ribose Chemical compound OC[C@@H]1O[C@H](O)[C@@H](O)[C@H]1O HMFHBZSHGGEWLO-FCAWWPLPSA-N 0.000 description 2
- 229940017687 beta-d-ribose Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- PAHUTFPWSUWSCR-BHPSOXLSSA-N (z)-2-methylbut-2-enedioic acid Chemical compound OC(=O)C(/C)=C\C(O)=O.OC(=O)C(/C)=C\C(O)=O PAHUTFPWSUWSCR-BHPSOXLSSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- GIEGKXINITVUOO-UHFFFAOYSA-N 2-methylidenebutanedioic acid Chemical compound OC(=O)CC(=C)C(O)=O.OC(=O)CC(=C)C(O)=O GIEGKXINITVUOO-UHFFFAOYSA-N 0.000 description 1
- ILKNNHYSEPMBSD-UHFFFAOYSA-N 4-methoxyphenol Chemical class COC1=CC=C(O)C=C1.COC1=CC=C(O)C=C1 ILKNNHYSEPMBSD-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- RXRDEBMRYAAFTQ-DFWYDOINSA-N N[C@@H](CCC(N)=O)C(=O)O.C(CCCC(=O)O)(=O)O Chemical compound N[C@@H](CCC(N)=O)C(=O)O.C(CCCC(=O)O)(=O)O RXRDEBMRYAAFTQ-DFWYDOINSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- LJSAJMXWXGSVNA-UHFFFAOYSA-N a805044 Chemical compound OC1=CC=C(O)C=C1.OC1=CC=C(O)C=C1 LJSAJMXWXGSVNA-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- BOAMTGHGHLIYHH-UHFFFAOYSA-N cyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C=C1.O=C1C=CC(=O)C=C1 BOAMTGHGHLIYHH-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDJXVNRFAQSMAA-UHFFFAOYSA-N quinhydrone Chemical compound OC1=CC=C(O)C=C1.O=C1C=CC(=O)C=C1 BDJXVNRFAQSMAA-UHFFFAOYSA-N 0.000 description 1
- 229940052881 quinhydrone Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
本公开涉及含有氢醌或其衍生物的稳定化组合物，一种确保氢醌或其衍生物的稳定性的组合物，在该组合物中，含有氢醌或其衍生物作为美白用有效成分，并且附加地包含金属氧化物(优选氧化锌(ZnO)、炉甘石(Calamine)、二氧化钛(TIO2)或其混合物)作为用于改善皮肤刺激的成分。为了确保这种稳定性，本公开的组合物包含(i)偏亚硫酸氢钠(Sodium metabisulfite)、亚硫酸氢钠(Sodium bisulfite)或其混合物、以及(ii)二元羧酸、三元羧酸或其混合物。
Description
技术领域
本公开涉及一种组合物，该组合物在含有对皮肤美白等有用的氢醌或其衍生物的同时，不仅减少皮肤刺激，而且同时确保氢醌或其衍生物的稳定性。
背景技术
为了防止皮肤色素沉着，利用了通过阻碍黑色素生成过程中的部分过程来抑制黑色素生成的方法。作为这种美白剂，在化妆品中一直利用抗坏血酸、熊果苷、曲酸等，但美白效果并不高。
氢醌(hydroquinone)或其衍生物与上述美白成分相比，美白效果优异。然而，氢醌或其衍生物被空气、热和/或光氧化而容易变色，并且在氧化时可能对黑色素生成细胞有毒性。具体而言，氧化的氢醌经过对苯醌(p-benzoquinone)而生成醌氢醌(Quinhydrone)，已知它们具有诱发细胞毒性、致癌和致敏的特性。由于这种不稳定性，各国只允许有限浓度的氢醌。
为了防止氢醌的氧化等，已经报道了将pH调节至4附近或应用多种抗氧化剂的方法。然而，在常规方法中，抗氧化剂本身发生变色或来自氢醌的刺激担忧仍然存在。这种刺激反而可能会引起副作用，例如炎症后色素沉着过度(post-inflammatoryhyperpigmentation)等。
虽然可以尝试克服这种氢醌的任意一个缺点，但难以同时满足上述两个缺点，即氢醌的刺激性和不稳定性。
发明内容
要解决的课题
因此，本公开要解决的课题是提供一种含有氢醌或其衍生物的组合物，其减少了皮肤刺激，同时确保了稳定性(stability)。
课题的解决手段
为了解决上述课题，本公开提供一种含有氢醌或其衍生物的组合物、优选化妆料或药学组合物，其特征在于，在含有氢醌或其衍生物作为有效成分，并且附加地包含金属氧化物(优选氧化锌(ZnO)、炉甘石(Calamine)、二氧化钛(TiO2)或其混合物、更优选氧化锌、炉甘石或其混合物)的组合物中，为了改善氢醌或其衍生物的稳定性，包含(i)偏亚硫酸氢钠(Sodium metabisulfite)、亚硫酸氢钠(Sodium bisulfite)或其混合物、以及(ii)二元羧酸(bi-carboxylic acid)、三元羧酸(tri-carboxylic acid)或其混合物。
本发明人确认了，用于皮肤美白等的用途的氢醌(Hydroquinone)或其衍生物具有皮肤刺激，这种皮肤刺激可以通过添加氧化锌(ZnO)、炉甘石(Calamine、氧化锌和氧化铁混合物)、二氧化钛(TIO2)等金属氧化物或其混合物来减少，但是当同时包含氢醌和金属氧化物时，金属氧化物成分进一步加速氢醌的氧化，反而存在氢醌氧化褐变的问题。即使利用各种已知的手段，这些问题也不容易解决。本发明人确认了通过组合使用上述(i)和(ii)的添加剂，可使氢醌或其衍生物的皮肤刺激非常低，同时实现高稳定性，从而完成了本发明。
在本公开中，本发明的化妆料或药学组合物含有氢醌或其衍生物作为美白有效成分。优选地，本发明的化妆料或药学组合物含有氢醌作为美白有效成分。
在本公开中，作为上述氢醌的衍生物，可以利用熊果苷(arbutin)、4-羟基茴香醚(4-hydroxyanisole)、氢醌单苄醚、氢醌单甲醚、氢醌单乙醚、叔丁基氢醌、4-[(四氢-2H-吡喃-2-基)氧基]苯酚、4-[(四氢-2H-噻喃-2-基)氧基]苯酚、氢醌葡糖苷衍生物(例如，氢醌α-D-葡萄糖(hydroquinoneα-D-glucose)、氢醌β-D-葡萄糖(hydroquinoneβ-D-glucose)、氢醌α-L-葡萄糖(hydroquinoneα-L-glucose)、氢醌β-L-葡萄糖(hydroquinoneβ-L-glucose)、氢醌α-D-半乳糖(hydroquinoneα-D-galactose)、氢醌β-D-半乳糖(hydroquinoneβ-D-galactose)、氢醌α-L-半乳糖(hydroquinoneα-L-galactose)、氢醌β-L-半乳糖(hydroquinoneβ-L-galactose)、氢醌α-D-核糖(hydroquinoneα-D-ribose)、氢醌β-D-核糖(hydroquinoneβ-D-ribose)、氢醌α-L-核糖(hydroquinoneα-L-ribose)、氢醌β-L-核糖(hydroquinoneβ-L-ribose)、氢醌α-D-阿拉伯糖(hydroquinoneα-D-arabinose)、氢醌β-D-阿拉伯糖(hydroquinoneβ-D-arabinose)、氢醌α-L-阿拉伯糖(hydroquinoneα-L-arabinose)、氢醌β-L-阿拉伯糖(hydroquinoneβ-L-arabinose)、氢醌α-D-葡萄糖胺(hydroquinoneα-D-glucosamine)、氢醌β-D-葡萄糖胺(hydroquinoneβ-D-glucosamine)、氢醌α-L-葡萄糖胺(hydroquinoneα-L-glucosamine)、氢醌β-L-葡萄糖胺(hydroquinoneβ-L-glucosamine)、氢醌α-D-半乳糖胺(hydroquinoneα-D-galactosamine)、氢醌β-D-半乳糖胺(hydroquinoneβ-D-galactosamine)、氢醌α-L-半乳糖胺(hydroquinoneα-L-galactosamine)和氢醌β-L-半乳糖胺(hydroquinioneβ-L-galactosamine)、氢醌α-D-葡萄糖醛酸(hydroquinoneα-D-glucuronic acid)、氢醌β-D-葡萄糖醛酸(hydroquinoneβ-D-glucuronic acid)、氢醌α-L-葡萄糖醛酸(hydroquinoneα-L-glucuronic acid)、氢醌β-L-葡萄糖醛酸(hydroquinoneβ-L-glucuronic acid)、氢醌α-D-半乳糖醛酸(hydroquinoneα-D-galacturonic acid)、氢醌β-D-半乳糖醛酸(hydroquinoneβ-D-galacturonic acid)、氢醌α-L-半乳糖醛酸(hydroquinoneα-L-galacturonic acid)以及氢醌β-L-半乳糖醛酸(hydroquinoneβ-L-galacturonic acid))等。在本发明的优选的一个方面，上述氢醌的衍生物是选自由氢醌单苄醚、氢醌单甲醚和氢醌单乙醚组成的组中的一种以上。
相对于组合物总重量，这种氢醌或其衍生物可以以0.1～10重量％的量含有，优选以0.5～10重量％的量含有。当以10重量％以上的量含有时，对皮肤的刺激担忧高，反而可能会诱发副作用，例如由于刺激引起的炎症后的色素沉着过度。
本发明的组合物包含用于减少皮肤刺激的金属氧化物，作为这种金属氧化物，可以使用选自由氧化锌、炉甘石、二氧化钛、氧化铁、氧化铝等组成的组中的一种或两种以上的混合物。在本发明的一个方面，上述金属氧化物是氧化锌、二氧化钛、炉甘石或其混合物。在本发明的优选的一个方面，上述金属氧化物是氧化锌、炉甘石或其混合物。
在本公开的组合物中，相对于组合物总重量，为了减少皮肤刺激而使用的金属氧化物的总含量可以以0.1～20重量％含有，优选以1～15重量％含有。
在本公开中，作为上述二元羧酸或三元羧酸，可以使用苹果酸(malic acid)、琥珀酸(succinic acid)、酒石酸(tartaric acid)、马来酸(maleic acid)、富马酸(fumaricacid)、柠檬酸(citric acid)、己二酸(adipic acid)、草酸(oxalic acid)、丙二酸(malonic acid)、戊二酸(glutaric acid)、戊烯二酸(glutaconic acid)、癸二酸(sebacicacid)、壬二酸(azelaic acid)、庚二酸(pimelic acid)、异柠檬酸(isocitric acid)、乌头酸(aconitic acid)、松蕈酸(agaric acid)、衣康酸(itaconic acid)、柠康酸(citraconicacid)、粘康酸(muconic acid)、戊炔二酸(glutinic acid)或其混合物。在本发明的优选的一个方面，上述二元羧酸或三元羧酸是柠檬酸、琥珀酸、己二酸、酒石酸或其混合物。
优选地，本公开的组合物包含(i)偏亚硫酸氢钠(Sodium metabisulfite)、以及(ii)柠檬酸、琥珀酸、己二酸、酒石酸或其混合物分别作为上述(i)和(ii)成分。
在本发明中，为了氢醌或其衍生物的稳定化，本发明的组合物必须包含(i)和(ii)成分全部，优选地(i)成分和(ii)成分的混合比例为3:7-7:3重量比范围。
在本发明的一个方面，相对于组合物总重量，上述(i)和(ii)成分的总含量优选为0.1重量％以上，优选为0.1至10重量％，更优选为0.1至5重量％，甚至更优选为0.2至5重量％。当以比这少的量含有时，则难以期待对氢醌的氧化防止效果，当使用比这多时，则存在稳定化剂本身可能会诱发皮肤刺激的担忧。
在本发明的一个方面，相对于组合物总重量，本发明的组合物中(i)和(ii)成分的总含量为0.1至10重量％，(i)和(ii)成分的混合比例为3:7-7:3重量比。
当上述(i)和(ii)成分的两种稳定化剂单独使用时，难以期待充分的稳定化效果。即，(i)和(ii)成分都是必需的，优选地将两种相互混合，其混合重量比例应以7:3～3:7的比例使用，才能使氢醌或其衍生物的变色防止效果变得更加优异。
本发明的一个方面，提供一种含有氢醌或其衍生物的组合物，其包含相对于组合物总重量的0.1至10重量％的氢醌或其衍生物；1至15重量％的氧化锌(ZnO)、炉甘石(Calamine)或其混合物；以及余量的溶剂，包含(i)偏亚硫酸氢钠(Sodiummetabisulfite)、亚硫酸氢钠(Sodium bisulfite)或其混合物、以及(ii)二元羧酸、三元羧酸或其混合物，上述(i)成分和(ii)成分的总量为相对于组合物总重量的0.1至5重量％，并且上述(i)成分和(ii)成分以3:7至7:3的重量比包含。
本公开的化妆料或药学组合物可以在不损害本发明目的的范围内包含多种化妆料或药学组合物用添加剂。此时，其他添加剂占除上述氢醌或其衍生物；金属氧化物(优选氧化锌(ZnO)、炉甘石(Calamine)、二氧化钛(TIO2)或其混合物，更优选氧化锌、炉甘石或其混合物)；(i)成分；以及(ii)成分之外的重量。
例如，除了前面提及的成分之外，本公开的化妆料组合物可以含有余量的溶剂。即，作为溶解氢醌或其衍生物的物质，水、亲水性溶剂或其混合物可以占除上述氢醌或其衍生物；氧化锌(ZnO)、炉甘石(Calamine)、二氧化钛(TIO2)等金属氧化物或其混合物；(i)成分；以及(ii)成分之外的重量。作为这种亲水性溶剂，可以使用多元醇或挥发性有机溶剂，其种类没有限制。具体而言，包括聚乙二醇、丙二醇、二丙二醇、甘油、1,3-丁二醇、异丙醇、乙醇等，但不限于此。优选地，可以使用异丙醇或乙醇，并且相对于组合物的总重量，上述亲水性溶剂可以以5～80重量％的量使用。亲水性溶剂的使用在本发明中没有限制，但当使用时可有助于氢醌或其衍生物的稳定性。
本公开的化妆料或药学组合物可以根据本领域中利用的常规制造方法制备。例如，本公开的组合物可以剂型化为爽肤水、精华、凝胶、露、霜、粉、贴剂等的形式并多种多样地应用，并且如果应用于皮肤，则可提供美白效果的功效。
本发明中记载的所有成分优选地不超过韩国、中国、美国、欧洲、日本等的相关法规、规范(例如，化妆品安全标准等相关规定(韩国)、化妆品安全技术规范(中国)、卫生规范(中国))等中规定的最大使用值。即，优选地，本发明的化妆料、药学或个人护理用组合物以各国的相关法规、规范中允许的含量限度包含本发明的成分。
发明效果
本公开提供一种含有氢醌或其衍生物的组合物，其改善了皮肤刺激同时确保了稳定性。具体而言，本公开的组合物具有以下优点：通过防止因外部环境因素(例如热、氧气、光等)和氧化锌等引起的氢醌或其衍生物的加速氧化反应来增加保存稳定性，并预防变色，从而可以降低毒性并减少炎症反应。本公开的组合物可以改善保存稳定性、生物相容性、皮肤美白功效等，因此可以广泛应用于美白改善用化妆品和医药品。
附图说明
图1是根据包含氢醌和作为金属氧化物的炉甘石的制剂中为了提高保存稳定性而使用的两种抗氧化剂的混合比例评价是否变色的结果。
图2是根据抗氧化剂种类的变色减少效果评价结果。
图3是根据抗氧化剂中酸(acid)种类的变色减少效果评价结果。
图4是根据两种抗氧化剂的总含量的变色减少效果评价结果。
具体实施方式
在下文中，为了帮助理解本发明，将列举实施例等进行详细描述。然而，本发明的实施例可以变形为各种不同形式，并且本发明的范围不应被解释为限于以下实施例。本发明的实施例是为了向本发明所属领域的普通技术人员更完整地描述本发明而提供的。
[实施例1～5和比较例1～6]
比较根据氢醌和金属氧化物(炉甘石)复合组合物中两种抗氧化剂比例的变色度
按照下表1所示的组成制备实施例1～5和比较例1～6并评价。
[表1]
具体而言，如下制备。根据上表1的比例，将亲水性溶剂和抗氧化剂1和2在室温下混合。在利用均质混合器(homomixer)以3000rpm搅拌的同时，投入作为金属氧化物的炉甘石，并分散。当炉甘石通过搅拌15分钟充分均匀分散时，添加氢醌并以3000rpm搅拌5分钟以完全溶解。
变色度如下测量。为了确认上表1组合物的保存稳定性，在50℃下保存4周。之后，将金属氧化物沉淀而下沉的上清液各200ul转载至96孔不透明白色板(white plate)中。此后，用Chromameter CR-400(美能达公司，日本)反复测量L值(亮度，lightness)、a值(红度，redness)、b值(黄度，yellowness)3次。整体变色度用
值表示。
其结果示于表1和图1。与实施例1～5一样，当两种抗氧化剂的重量比例为3:7～7:3比例时，变色度显示出2.5以下的低数值。相反，在比较例1～6的比例中，变色度为18以上，色差度高。由此可以看出，两种抗氧化剂对于改善稳定性都是必需的。
另外，由于两种抗氧化剂都是必需的，优选地，当将两种抗氧化剂以特定比例混合并使用时，可以提高金属氧化物和氢醌的复合组合物中氢醌的保存稳定性。
[实施例6～7和比较例7～10]
比较根据氢醌和金属氧化物(炉甘石)复合组合物中抗氧化剂种类的变色度
按照下表2所示的组成制备实施例6～7和比较例7～10并评价。制备方法和变色度测量方法与上述实施例1～5的方法相同。
[表2]
其结果示于表2和图2。在实施例6和7中，变色度显示出2.1以下的低数值。相反，在比较例7～10中，变色度为16.3以上，较高。因此，对于抗氧化剂的种类，只有使用与实施例6和7相同的种类，才能提高金属氧化物和氢醌的复合组合物中氢醌的保存稳定性。
[实施例6、8、9和比较例11～15]
比较根据氢醌和金属氧化物(炉甘石)复合组合物中酸(acid)的种类的变色度
按照下表3所示的组成制备实施例6、8、9和比较例11～15并评价。制备方法和变色度测量方法与上述实施例1～5的方法相同。
[表3]
其结果示于表3和图3。与实施例6、8和9一样，当用作抗氧化剂的酸的种类为二元或三元羧酸时，变色度为2.4以下，较低。然而，当使用与比较例11～15相同的其他酸时，变色度为28.9以上，较高。因此，作为抗氧化剂中酸的种类，只有使用二元或三元羧酸，才能提高金属氧化物和氢醌的复合组合物中氢醌的保存稳定性。
[实施例3、10和11]
比较根据氢醌和金属氧化物(炉甘石)复合组合物中两种抗氧化剂总量的变色度
按照下表4所示的组成制备实施例3、10和11并评价。制备方法和变色度测量方法与上述实施例1～5的方法相同。
[表4]
| 构成 | 成分(单位：重量％) | 实施例3 | 实施例10 | 实施例11 |
| 有效成分 | 氢醌 | 4 | 4 | 4 |
| 金属氧化物 | 炉甘石 | 8 | 8 | 8 |
| 亲水性溶剂 | 二丙二醇 | 10 | 10 | 10 |
| 亲水性溶剂 | 乙醇 | 至100 | 至100 | 至100 |
| 抗氧化剂1 | 柠檬酸 | 0.15 | 0.1 | 0.05 |
| 抗氧化剂2 | 偏亚硫酸氢钠 | 0.15 | 0.1 | 0.05 |
| 变色度ΔE | 1.8 | 2.1 | 6.1 |
其结果示于表4和图4。即，在上表1中确认的两种抗氧化剂的比例(1:1重量比)中改变抗氧化剂的总量来评价组合物的变色度。如表4和图4所示，在实施例3、10和11中，变色度均显示出6.1以下的低数值。因此，当将两种抗氧化剂以特定比例混合且其总量为0.1重量％以上时，在金属氧化物和氢醌的复合组合物中对氢醌的氧化防止效果优异。
Claims (8)
1.一种含有氢醌或其衍生物的组合物，其特征在于，在含有氢醌或其衍生物作为有效成分，并且附加地包含金属氧化物的组合物中，
为了改善氢醌或其衍生物的稳定性，包含(i)偏亚硫酸氢钠(Sodium metabisulfite)、亚硫酸氢钠(Sodium bisulfite)或其混合物、以及(ii)二元羧酸、三元羧酸或其混合物。
2.如权利要求1所述的组合物，其中，所述氢醌的衍生物是选自由氢醌单苄醚、氢醌单甲醚、氢醌单乙醚、熊果苷(arbutin)、4-羟基茴香醚(4-hydroxyanisol)、叔丁基氢醌、4-[(四氢-2H-吡喃-2-基)氧基]苯酚、4-[(四氢-2H-噻喃-2-基)氧基]苯酚和氢醌葡糖苷衍生物组成的组中的任意一种以上。
3.如权利要求1所述的组合物，其中，所述二元羧酸或三元羧酸是苹果酸(malicacid)、琥珀酸(succinic acid)、酒石酸(tartaric acid)、马来酸(maleic acid)、富马酸(fumaric acid)、柠檬酸(citric acid)、己二酸(adipic acid)、草酸(oxalic acid)、丙二酸(malonic acid)、戊二酸(glutaric acid)、戊烯二酸(glutaconic acid)、癸二酸(sebacic acid)、壬二酸(azelaic acid)、庚二酸(pimelic acid)、异柠檬酸(isocitricacid)、乌头酸(aconitic acid)、松蕈酸(agaric acid)、衣康酸(itaconic acid)、柠康酸(citraconic acid)、粘康酸(muconic acid)、戊炔二酸(glutinic acid)或其混合物。
4.如权利要求1所述的组合物，其中，所述金属氧化物是氧化锌(ZnO)、炉甘石(Calamine)或其混合物。
5.如权利要求1所述的组合物，其中，所述组合物包含(i)偏亚硫酸氢钠(Sodiummetabisulfite)、以及(ii)柠檬酸、琥珀酸、己二酸、酒石酸或其混合物。
6.如权利要求1至5中任一项所述的组合物，其中，所述组合物包含重量比((i):(ii))为3:7至7:3的(i)偏亚硫酸氢钠(Sodium metabisulfite)、亚硫酸氢钠(Sodiumbisulfite)或其混合物、以及(ii)二元羧酸、三元羧酸或其混合物。
7.如权利要求6所述的组合物，其中，相对于组合物总重量，所述组合物的(i)偏亚硫酸氢钠(Sodium metabisulfite)、亚硫酸氢钠(Sodium bisulfite)或其混合物、以及(ii)二元羧酸、三元羧酸或其混合物的总含量为0.1至10重量％。
8.一种含有氢醌或其衍生物的组合物，其包含相对于组合物总重量的0.1至10重量％的氢醌或其衍生物；1至15重量％的氧化锌(ZnO)、炉甘石(Calamine)或其混合物；以及余量的溶剂，
包含(i)偏亚硫酸氢钠(Sodium metabisulfite)、亚硫酸氢钠(Sodium bisulfite)或其混合物、以及(ii)二元羧酸、三元羧酸或其混合物，所述(i)成分和(ii)成分的总量为相对于组合物总重量的0.1至5重量％，
所述(i)成分和(ii)成分以3:7至7:3的重量比包含。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142222 | 2020-10-29 | ||
| KR10-2020-0142222 | 2020-10-29 | ||
| KR10-2021-0114285 | 2021-08-27 | ||
| KR1020210114285A KR20220057415A (ko) | 2020-10-29 | 2021-08-27 | 히드로퀴논 또는 이의 유도체를 함유하는 안정화 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114425024A true CN114425024A (zh) | 2022-05-03 |
Family
ID=81311955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111197165.9A Pending CN114425024A (zh) | 2020-10-29 | 2021-10-14 | 含有氢醌或其衍生物的稳定化组合物 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN114425024A (zh) |
| TW (1) | TW202220640A (zh) |
| WO (1) | WO2022092639A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115006279A (zh) * | 2022-06-21 | 2022-09-06 | 沈阳药科大学 | 一种包合物及其制备方法、一种外用制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09263513A (ja) * | 1996-03-29 | 1997-10-07 | Shiseido Co Ltd | 皮膚外用剤 |
| JP2000204019A (ja) * | 1999-01-14 | 2000-07-25 | Pola Chem Ind Inc | 美白効果を有するメ―クアップ化粧料 |
| US7189759B2 (en) * | 2001-05-23 | 2007-03-13 | Medicis Pharmaceutical Corporation | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| JP3712066B2 (ja) * | 2002-09-10 | 2005-11-02 | 財団法人理工学振興会 | ハイドロキノンと界面活性剤の結晶性の分子錯体を含む美白剤 |
| KR101661694B1 (ko) * | 2014-07-29 | 2016-10-10 | 동아제약 주식회사 | 히드로퀴논을 포함하는 저자극성 피부 미백용 조성물 |
-
2021
- 2021-10-14 WO PCT/KR2021/014281 patent/WO2022092639A1/ko active Application Filing
- 2021-10-14 CN CN202111197165.9A patent/CN114425024A/zh active Pending
- 2021-10-28 TW TW110140168A patent/TW202220640A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022092639A1 (ko) | 2022-05-05 |
| TW202220640A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5062708B2 (ja) | 防腐殺菌剤及び人体施用組成物 | |
| EP0304627B1 (de) | Antimikrobiell wirksame, aromatisierte Zubereitungen | |
| EP1543829B2 (en) | Antiseptic bactericides containing an 1,2-alkanediol and aromatic compound(s) and cosmetics, drugs and foods containing the antiseptic bactericides | |
| KR100740393B1 (ko) | 미녹시딜 함유 제제 | |
| US6641845B1 (en) | Skin whitening composition comprising bearberry and tetrahydrocurcumin | |
| DE60012820T2 (de) | Zusammensetzungen zur Stabilisierung von sauerstoffempfindlichen Verbindungen | |
| US20040185016A1 (en) | Compositions for treatment of hyperpigmentation and methods for making and using such compositions | |
| KR102081788B1 (ko) | 비타민 c 안정화 조성물, 이의 제조방법 및 이를 포함하는 화장료 조성물 | |
| CN114425024A (zh) | 含有氢醌或其衍生物的稳定化组合物 | |
| KR102183186B1 (ko) | 고농도 비타민 c를 함유하는 화장료 조성물 | |
| US20020141955A1 (en) | Method for slowing the decomposition of a cosmetic composition | |
| JP2023097373A (ja) | シゾフィランの組成物及びその調製方法および応用 | |
| US7223382B2 (en) | Cosmetic compositions containing rosemary extract and DHA | |
| WO2002096371A1 (en) | Cosmetic compositions containing rosemary extract and dha | |
| KR20220057415A (ko) | 히드로퀴논 또는 이의 유도체를 함유하는 안정화 조성물 | |
| JP2008195688A (ja) | 防腐殺菌保湿剤及び皮膚・毛髪外用組成物 | |
| KR100297347B1 (ko) | 안정화된l-아스코르빈산을함유하는유중수형에멀젼화장료조성물및그의제조방법 | |
| US3123528A (en) | New therapeutic compositions | |
| US11872297B2 (en) | Anti-acne composition | |
| KR102348583B1 (ko) | 천연색소 변색방지용 조성물 | |
| JPH04300812A (ja) | 活性酸素消去剤 | |
| CN113398007A (zh) | 一种单剂型空气氧化的染发剂和制备方法及染发方法 | |
| KR102528738B1 (ko) | 물을 포함하지 않으면서 순수비타민 c를 고함량 함유하는 화장료 조성물 | |
| JPH0372202B2 (zh) | ||
| KR102418845B1 (ko) | 비타민 c를 포함하는 파우더형 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |